Neumora Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Selling, General & Admin	62.54	45.48	31.12	24.55	8.39	Upgrade
Research & Development	200.93	142.72	91.75	55.78	17.31	Upgrade
Operating Expenses	263.46	188.19	122.87	80.32	25.71	Upgrade
Operating Income	-263.46	-188.19	-122.87	-80.32	-25.71	Upgrade
Interest & Investment Income	19.93	16.61	4.56	-	-	Upgrade
Other Non Operating Income (Expenses)	-0.08	-0.17	0.41	0.01	-0.08	Upgrade
EBT Excluding Unusual Items	-243.61	-171.75	-117.9	-80.31	-25.79	Upgrade
Merger & Restructuring Charges	-	-	-	-	-0.7	Upgrade
Other Unusual Items	-	-	-	-	-3.28	Upgrade
Pretax Income	-243.61	-235.66	-130.9	-237.31	-99.27	Upgrade
Income Tax Expense	0.18	0.27	-	-	-	Upgrade
Net Income	-243.79	-235.93	-130.9	-237.31	-99.27	Upgrade
Net Income to Common	-243.79	-235.93	-130.9	-237.31	-99.27	Upgrade
Shares Outstanding (Basic)	159	65	27	22	13	Upgrade
Shares Outstanding (Diluted)	159	65	27	22	13	Upgrade
Shares Change (YoY)	145.12%	138.99%	24.25%	68.46%	-	Upgrade
EPS (Basic)	-1.53	-3.63	-4.81	-10.84	-7.64	Upgrade
EPS (Diluted)	-1.53	-3.63	-4.81	-10.84	-7.64	Upgrade
Free Cash Flow	-182.94	-163.4	-115.41	-76.24	-28.06	Upgrade
Free Cash Flow Per Share	-1.15	-2.51	-4.24	-3.48	-2.16	Upgrade
EBITDA	-262.83	-187.53	-122.28	-79.79	-25.6	Upgrade
D&A For EBITDA	0.63	0.67	0.59	0.54	0.11	Upgrade
EBIT	-263.46	-188.19	-122.87	-80.32	-25.71	Upgrade

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q